FDA issues variant-related SARS-CoV-2 test requirements


The FDA has made amendments to conditions of authorization for some SARS-CoV-2 tests with emergency use authorization. Test makers must provide updated authorized labeling to the FDA within three months as a supplement to the EUA, and they must evaluate their tests' performance on viral mutations.

Full story:

FDLI SmartBrief

The latest regulatory and company news on food, drugs, animal drugs, biologics, cosmetics, diagnostics, dietary supplements, medical devices and tobacco

Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition.